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Abstract
Background: Neuroinflammation has gained increasing attention as a potential contributing factor in the onset
and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of selected
cerebrospinal fluid (CSF) inflammatory and neuronal degeneration markers with signature CSF AD profile and
cognitive functions among subjects at the symptomatic pre- and early dementia stages.
Methods: In this cross-sectional study, 52 subjects were selected from an Icelandic memory clinic cohort. Subjects were
classified as having AD (n = 28, age = 70, 39% female, Mini-Mental State Examination [MMSE] = 27) or non-AD (n= 24,
age = 67, 33% female, MMSE = 28) profile based on the ratio between CSF total-tau (T-tau) and amyloid-β1–42 (Aβ42)
values (cut-off point chosen as 0.52). Novel CSF biomarkers included neurofilament light (NFL), YKL-40, S100 calcium-
binding protein B (S100B) and glial fibrillary acidic protein (GFAP), measured with enzyme-linked immunosorbent assays
(ELISAs). Subjects underwent neuropsychological assessment for evaluation of different cognitive domains, including
verbal episodic memory, non-verbal episodic memory, language, processing speed, and executive functions.
Results: Accuracy coefficient for distinguishing between the two CSF profiles was calculated for each CSF marker and
test. Novel CSF markers performed poorly (area under curve [AUC] coefficients ranging from 0.61 to 0.64) compared to
tests reflecting verbal episodic memory, which all performed fair (AUC > 70). LASSO regression with a stability approach
was applied for the selection of CSF markers and demographic variables predicting performance on each cognitive
domain, both among all subjects and only those with a CSF AD profile. Relationships between CSF markers and cognitive
domains, where the CSF marker reached stability selection criteria of > 75%, were visualized with scatter plots. Before
calculations of corresponding Pearson’s correlations coefficients, composite scores for cognitive domains were adjusted
for age and education. GFAP correlated with executive functions (r = − 0.37,
p = 0.01) overall, while GFAP correlated with processing speed (r = − 0.68, p< 0.001) and NFL with verbal episodic
memory (r = − 0.43, p = 0.02) among subjects with a CSF AD profile.
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Conclusions: The novel CSF markers NFL and GFAP show potential as markers for cognitive decline among individuals
with core AD pathology at the symptomatic pre- and early stages of dementia.
Keywords: Alzheimer’s disease, Cerebrospinal fluid, Neurofilament light, YKL-40, S100 calcium-binding protein B, Glial
fibrillary acidic protein, AD biomarker profile, Cognitive domains
Introduction
In recent years, a paradigm shift in the research criteria
of Alzheimer’s disease (AD) has occurred as the primary
focus has shifted from clinical to biological criteria. The
emphasis is now on the pathology [1], which is believed
to start decades before the appearance of clinical symp-
toms [2]. The core cerebrospinal fluid (CSF) biomarkers
reflecting the hallmarks of AD pathology, extracellular
amyloid plaques (Aβ), and neurodegeneration (total tau
[T-tau] and phosphorylated tau [P-tau]) have been at the
center of this shift and have been extensively studied [3].
Although the diagnostic accuracies of these markers are
generally satisfactory [4], their levels are relatively con-
stant in the symptomatic stages of the disease and do
not correlate well with the progression of cognitive de-
cline [5–7]. This necessitates the need for exploration of
novel biomarkers that help in better understanding the
different aspects of AD pathology, its progression, and
clinical manifestation.
Increasing evidence shows that inflammation is a con-
tributing factor in the pathogenesis and development of
AD and other neurodegenerative diseases [8, 9]. A num-
ber of studies show that Aβ toxicity and plaques induce
an immune response, including activation of astrocytes
and microglia, the immune cells of the brain [10–12]. Fur-
thermore, activation of these cells is also thought to play a
role in the formation and progression of neurofibrillary
tangles (NFTs), contributing to neuronal dysfunction and
loss [13]. Glial activation markers are, therefore, of high
interest when it comes to exploring new biomarkers for
the diagnosis of dementia.
The glial proteins YKL-40 (also known as chitinase-3-
like-1 protein), S100 calcium-binding protein B (S100B),
and glial fibrillary acidic protein (GFAP) have previously
been associated with AD pathology [14]. All are
expressed in astrocytes within the central nervous sys-
tem (CNS), primarily (YKL-40 and S100B) [15, 16] or
exclusively (GFAP) [17]. YKL-40, a chitin-binding glyco-
protein and a glial activation marker [18], has been iden-
tified inside reactive astrocytes in close proximity to
amyloid plaques [19]. YKL-40 expression also correlates
with tau pathology in AD brain tissues, demonstrating
an association between glial activation and neurodegen-
eration [20]. S100B is a calcium-binding protein, exert-
ing both intracellular and extracellular functions and has
been found to be upregulated in AD tissues [21, 22].
GFAP is a key intermediate filament protein and marker
of reactive astrocytes, whose expression has been associ-
ated with amyloid plaque load and, to a lesser extent,
the number of NFTs [23–25].
Inflammation in the brain and its role in AD can be
studied indirectly through the analysis of CSF proteins. In-
creased levels of CSF YKL-40, S100B, and GFAP have
been observed in AD patients compared to healthy con-
trols, although results have not been consistent [26]. The
relationship between inflammatory and core AD markers
(Aβ, tau) in CSF has also been explored. Previous studies
have found a strong positive association between CSF
YKL-40 and tau proteins but not between YKL-40 and
Aβ42 [19, 27–29]. YKL-40 has also been shown to strongly
correlate with neuronal degeneration marker neurofila-
ment light (NFL) in CSF [30], further supporting the asso-
ciation between glial activation and neurodegeneration.
NFL is mainly located in myelinated axons. Therefore, its
levels also reflect white matter changes, with recent stud-
ies indicating a potential for this protein as both a
diagnostic and progression marker in AD and other neu-
rodegenerative diseases [26, 31]. Few studies have exam-
ined the relationship between S100B and GFAP with core
AD markers in CSF. Hov et al. [32] found an association
between S100B and P-tau but not Aβ42 among elective
surgery patients free from dementia and delirium. Ishiki
et al. [33] did not find an association between CSF GFAP
and core markers within a dementia cohort.
Loss of memory is typically among the first clinical
symptoms of AD, marking the beginning of cognitive de-
cline. The medial temporal lobe is an early site of tau ac-
cumulation, and its dysfunction may underlie episodic
memory decline [34]. Other cognitive domains are also
involved in AD, such as language, non-verbal episodic
memory, and executive functions [35].
In the most recent research criteria from the Inter-
national Working Group for the diagnosis of AD pub-
lished in 2014 [36], the diagnosis of prodromal AD
requires both the presence of cognitive symptoms and
AD signature biomarker profile (increased amyloid posi-
tron emission tomography [PET] deposition or the com-
bination of lowered CSF amyloid-β1–42 and elevated CSF
tau). It is essential for the evaluation of novel biomarkers
to examine their relationship with both entities separ-
ately, independent of diagnosis. That type of approach
could enhance both understanding of the underlying
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pathology of AD and the sequence of events leading to
cognitive impairment. The first aim of this study was to
assess the ability of glial (YKL-40, S100B, GFAP) and
neurodegeneration (NFL) markers in CSF to discrimin-
ate between different CSF profiles (AD and non-AD)
among subjects at the symptomatic pre- and early stages
of dementia. In addition, the results were compared to
the discrimination ability of neuropsychological tests,
which are commonly used to aid AD diagnosis. The sec-
ond aim was to investigate the relationship between the




Individuals, referred to The National University Hospital
of Iceland Memory Clinic during a 4-year period which
had (1) a score between 24 and 30 on the Mini-Mental
State Examination (MMSE) and (2) a score of 4.0 or less
on the Informant Questionnaire on Cognitive Decline in
the Elderly (IQCODE) [37], were invited to join a pro-
spective study on mild cognitive impairment (MCI, n =
218). The exclusion criteria were (1) cognitive impair-
ment that, without a doubt, could be explained by a con-
dition other than dementia; (2) difficulties participating
due to health or social issues; and (3) residency outside
the Reykjavík Capital Area. In entering the study, each
subject underwent various assessments, including a
standard clinical and neuropsychological assessment and
brain magnetic resonance imaging (MRI) for evaluation
of medial temporal lobe atrophy (MTA). Lumbar punc-
ture for collection of CSF, which was optional by the re-
quirement of the National Bioethics Committee, was
also carried out. For this particular study (Fig. 1), only
subjects with CSF samples and complete neuropsycho-
logical assessment were selected from the cohort (n =
56). The final sample included 52 subjects as four were
removed due to excessively high value on CSF GFAP
(n = 1) or blood-contamination in the CSF sample (n =
3). Clinical diagnosis of AD was based on the criteria for
probable AD dementia defined by the National Institute
on Aging-Alzheimer’s Association (NIA-AA) [38], with
evidence of AD pathophysiological processes (based on
MTA score or/and analysis of core CSF markers). Pa-
tients with Lewy body dementia (LBD) were diagnosed
based on the consensus criteria of McKeith et al. [39].
MCI diagnosis required the fulfillment of the Winblad
criteria [40], with those not fulfilling the criteria diag-
nosed as having subjective mild cognitive impairment
(SCI).
CSF collection and analysis
CSF was collected via lumbar puncture with a 22-gauge
spinal needle at the L3/4 or L4/5 interspace. Uncentri-
fuged samples were frozen in 2-ml polypropylene tubes
and stored at − 80 °C. Commercially available sandwich
enzyme-linked immunosorbent assays (ELISAs) were
used for measurements of all proteins. Analyses of core
AD markers T-tau (IBL International, Hamburg,
Germany) and Aβ42 (IBL International, Hamburg,
Germany) were carried out in the ISO 15189 accredited
medical laboratory MVZ Labor P.D. Dr. Volkmann und
Kollegen GbR (Karlsruhe, Germany). Assays for novel
markers NFL (Uman Diagnostics, Umeå, Sweden), YKL-
40 (Quantikine ELISA Human Chitinase-3–like 1; R&D
systems, M.N., USA), S100B (BioVendor GmbH, Heidel-
berg, Germany), and GFAP (BioVendor GmbH, Heidel-
berg, Germany) were performed in technical duplicates
Fig. 1 Flow diagram of sample selection
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and according to the manufacturer’s instructions in a la-
boratory at the University of Iceland. The mean Intra-
assay CV was < 10% and mean Inter-assay CV < 15% for
all assays.
Subject grouping based on CSF measures
Each subject was classified independently of clinical
diagnosis on the basis of CSF T-tau and Aβ42 values. T-
tau/Aβ42 ratio cut-off of 0.52 was chosen based on re-
sults from a large memory clinic cohort study [41], giv-
ing a sensitivity of 93% for AD and specificity of 83% for
controls. A positive CSF AD profile was defined as T-
tau/Aβ42 ratio > 0.52. The same ratio was also used as a
part of the clinical diagnosis of AD, explaining full con-
cordance with CSF AD profile.
Neuropsychological tests
All subjects underwent a detailed neuropsychological
assessment performed by licensed psychologists. Five
cognitive domains, commonly affected by aging and
AD, were assessed using seven tests (Table 1). For the
evaluation of verbal episodic memory, two tests were
used. The first, Rey Auditory Verbal Learning Test
(RAVLT), consisted of 15 nouns read aloud by the
examiner for five consecutive trials. Each trial was
followed by a free-recall test. After a 30-min delay, sub-
jects were required to recall the words without being
reread the list [42]. The second test was composed of a
story [43], which included 25 ideas verbally presented
by the examiner. Right after the story was presented
(immediate recall), the subject was asked to repeat what
they remembered without being given any clues (free
recall). Thirty minutes later, subjects were asked to re-
call the story again (delayed recall). The Rey–Osterrieth
complex figure test (ROCF) was used to assess non-
verbal episodic memory [42]. The subject was asked to
reproduce a complicated line drawing, first by copying
it free-hand, second by drawing from memory (immedi-
ate recall), and third by drawing it after a 30-min delay
(delay recall). Verbal fluency [44] was evaluated with
subjects having to produce as many animal names and
words starting with the letters H and S as possible in
60 s. Two subtests were used to evaluate processing
speed. Part A of The Trail Making Test (TMT-A) [45]
required subjects to connect 25 numbered circles posi-
tioned randomly on a piece of paper. The first and the
most simple part of the Stroop test—Word reading—
was also used for the evaluation of the same cognitive
domain [46]. Subjects were shown a list of color names
(red, green, yellow, or blue), each printed in black ink,
and told to read out loud as rapidly as possible. For
evaluation of executive functions, The Digit Symbol
Substitution Test (DSST), Trail making Test B (TMT-
B), and Stroop 4th/3rd parts were used. DSST [47] is a
paper-and-pencil test that requires the participant to
match symbols to numbers according to a key located
at the top of the page. The subject copied the symbol
into spaces below a row of numbers. The number of
correct symbols within 120 s, constituted the score.
TMT-B includes both numbers (1–13) and letters (A-
L), with the subject drawing lines between circles, alter-
nating between numbers and letters (1-A-2-B-3-C,
etc.). In Stroop—part 4, subjects had to name the color
of words when color and meaning were incongruent.
Part 3—naming of squares of given colors—was used to
control for speed by calculating the ratio between the
two parts.











Free recall—the sum of the
number of words recalled from
trials 1 through 5 (0 to 75)
RAVLT delayed
recall
Delayed free recall—number of






recognized from a list of 45
words. Number of false positives




Recall of a story containing 25
ideas (0 to 25)
Story delayed recall Recall of a story containing 25









ROCF delayed recall Complicated drawing reproduced
again after 30-min delay (0 to 36)
Language Verbal fluency
animals
Number of animal names
produced in 60 s
Verbal fluency H+S Number of words that begin with
H/S in 60 s
Processing
speed
TMT-A Time in seconds to connect a set
of 25 numbered dots in
sequential order
Stroop test, part I Time in seconds to read a set of
color words written in black
Executive
functions
DSST Number of symbols correctly
produced in 120 s
TMT-B Time in seconds to connect 25
targets, alternating between
numbers and letters
Stroop 4th/3rd part Part 3—time in seconds it takes
to name squares of given colors
Part 4—time in seconds it takes
to name the color of a word
Abbreviations: RAVLT Rey Auditory Verbal Learning Test, ROCF Rey–Osterrieth
complex figure, DSST Digit symbol substitution test, TMT Trail Making Test
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Statistical analysis
Descriptive group comparisons were performed using
Mann-Whitney U tests and chi-square tests for continu-
ous and categorical variables, respectively. Raw values of
CSF measures and selected neuropsychological tests
(TMT, Stroop test, DSST) were naturally log-
transformed to account for a non-normal distribution.
Composite scores for each cognitive domain were calcu-
lated by averaging neuropsychological test z-scores and
subsequently converting those scores into z-scores. Be-
fore the computation of composite scores, z-scores for
tests measuring reaction time were reversed (TMT,
Stroop test, DSST) for the purpose of test consistency
(higher scores always indicating better performance). Re-
ceiver operating characteristic (ROC) curves were con-
structed for the differentiation between CSF AD and
non-AD profiles. The discrimination abilities of each
CSF marker and cognitive domain were compared using
the area under the curve (AUC) method, according to
DeLong et al. [48]. The AUC is the probability that a
randomly selected pair of subjects from each CSF profile
group is correctly classified. Stability selection was
employed in combination with least absolute shrinkage
and selection operator (LASSO) regression for the pur-
pose of identifying stable predictors in multivariable
models [49]. LASSO is a penalized approach to multiple
regression and especially useful when dealing with multi-
collinearity (highly correlated predictors). A penalty is
introduced, reducing large variance due to multicolli-
nearity in exchange for a tolerable amount of bias. It also
performs variable selection as it imposes coefficients of
some variables to shrink towards zero. Stable selection is
based on resampling the data for avoidance of overfit-
ting, which can be advantageous when dealing with
smaller data sets. Instead of fitting one model on a
whole sample, many models are fitted on subsamples
drawn from it. Stability selection was performed by the
use of the function stabsel in the package stabs, imple-
menting the package glmnet for LASSO model fitting
[50, 51]. Cut-off value for stable selection was set to 75%
(the percentage of times a variable was selected into a
model) and per-family error rate (PFER) to 1 for all ana-
lyses. Each subsample was half the size of the original
one, with 100 subsamples being drawn. LASSO logistic
regression was applied for the selection of novel CSF
markers and composite tests, most accurately distin-
guishing between the two CSF profiles. LASSO linear re-
gression was used to select variables, out of CSF markers
and demographic variables, predicting with most accur-
acy the composite z-score for each cognitive domain.
Two LASSO regressions with a stability selection were
performed for each cognitive domain, one which in-
cluded all subjects and the other, which only included
those with a CSF AD profile. Scatter plots were used for
visualization of the selected relationships between CSF
markers and cognitive domains. Cognitive domain mea-
sures were adjusted for age and education before the cal-
culations of corresponding Pearson’s correlations
coefficients. For the adjustment, linear regression models
were created with each composite test z-score as the
dependent variable and age and education as independ-
ent variables. The residual for each subject was subse-
quently calculated (observed minus predicted score).
Significance values were not adjusted for multiple com-
parisons, as this study was viewed as explorative with
emphasis on discovering relationships. All statistical ana-
lyses were performed using R (version 3.6.1, The R
Foundation for Statistical Computing).
Results
Sample characteristics
Table 2 shows the demographic, pathophysiological, and
clinical characteristics of the cohort by CSF profile.
There were no significant differences between the
groups in age, length of education, novel CSF protein
levels, or gender frequencies. Boxplots comparing distri-
butions in CSF protein levels (NFL, YKL-40, S100B,
GFAP) between profile groups are presented in Add-
itional file 1, S1a-d. The CSF AD profile group showed
significantly worse performance on the MMSE, RAVLT,
Story, ROCF immediate recall, and Verbal fluency ani-
mal tests compared to the non-AD group (p < 0.05).
Pearson’s correlations between CSF markers
Pearson’s correlations between the CSF markers, age,
and length of education are presented in Fig. 2, respect-
ively. Inflammatory markers YKL-40 and S100B and
neurodegeneration markers NFL and T-tau all correlated
positively and significantly with each other. The highest
correlation was found between NFL and YKL-40 (NFL:
r = 0.62, p < 0.001). GFAP did only significantly correlate
with the CSF marker S100B (r = 0.53, p < 0.001). No CSF
markers correlated significantly with Aβ42. All the CSF
markers, except for Aβ42, correlated positively with age.
Length of education correlated weakly and negatively
with T-tau (r = − 0.29, p = 0.03).
Accuracy of CSF markers and cognitive domains in
distinguishing between CSF profiles
Accuracies for distinguishing between CSF AD and non-
AD profiles were based on univariable ROC analyses
(Table 3). AUCs for novel CSF markers ranged from
0.61 to 0.64, with a lower limit of each confidence inter-
val below the value of 0.5. In comparison, neuropsycho-
logical tests reflecting verbal episodic memory had the
highest accuracy compared to other measurements, with
all AUCs over 0.70, which is considered fair [52]. The
scores for the verbal episodic memory composite test
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Gender (M/F) 16/8 17/11 0.66
Age, years 67 (46–80) 70 (51–84) 0.17
Education, years 14.0 (9–20) 12.5 (6–17) 0.11
Clinical diagnosis
SCI/MCI/AD/LBD 10/13/0/1 2/9/16/1 N/Ab
CSF measures
Aβ42 (pg/ml) 703 (374–2332) 454 (160–822) N/A
c
T-tau (pg/ml) 173 (100–722) 416 (132–838) N/Ac
NFL (ng/ml) 1.9 (0.9–6.5) 2.5 (1.2–4.5) 0.15
YKL-40 (ng/ml) 165 (83–399) 203 (124–367) 0.12
S100B (pg/ml) 215 (132–335) 230 (129–458) 0.17
GFAP (ng/ml) 1.0 (0.1–7.1) 1.3 (0.5–21.3) 0.09
Cognitive domains
Global cognition
MMSE, score 28 (24–30) 27 (24–30) 0.01
Verbal episodic memory
RAVLT immediate recall, score 36 (23–66) 26.5 (13–51) 0.003
RAVLT delayed recall, score 6.5 (0–15) 1.5 (0–12) < 0.001
RAVLT recognition-fp, score 9.0 (3–15) 5.5 (−3–15) 0.003
Story immediate recall, score 13.5 (5–17) 8 (1–18) 0.005
Story delayed recall, score 12.0 (1–19) 5.5 (0–16) 0.002
Non-verbal episodic memory
ROCF immediate recall, score 13.3 (0–27) 7.3 (0–26) 0.04
ROCF delayed recall, score 12.8 (0–25) 8.5 (0–26) 0.07
Language
Verbal fluency animal, score 20 (8–33) 14 (4–27) 0.02
Verbal fluency H+S, score 24.0 (14–48) 25.5 (6–63) 1.00
Processing speed
TMT-A, seconds 43.5 (21–133) 48.0 (27–116) 0.22
Stroop—part I, seconds 23.5 (20–42) 24.5 (17–34) 0.64
Executive functions
TMT-B, seconds 109 (44–340) 153 (60–343) 0.06
DSST, score 8.5 (3–51) 7.0 (2–61) 0.24
Stroop 4th/3rd part, seconds 2.1 (1.4–4.0) 2.1 (1.6–5.8) 0.25
Abbreviations: AD Alzheimer’s disease, CSF cerebrospinal fluid, DDST Digit Symbol Substitution Test, fp false positives, LBD Lewy body dementia, MCI mild cognitive
impairment, MMSE Mini-Mental State Examination, N/A not applicable, RAVLT Rey Auditory-Verbal Learning Test, ROCF Rey–Osterrieth complex figure, SCI
subjective cognitive impairment, TMT Trail Making Test
Values are shown as median (range) or as numbers per group, aMann-Whitney U non-parametric tests used for continuous variables and chi-square tests for
categorical variables, p values not applicable for bclinical diagnosis due to CSF profiles being part of the diagnostic criteria for AD and cAβ42 and T-tau due to their
values used for defining CSF profiles
Teitsdottir et al. Alzheimer's Research & Therapy           (2020) 12:92 Page 6 of 14
(AUC = 0.80, CI 0.69–0.92) and RAVLT delayed recall
(AUC = 0.80, CI 0.68–0.93) distinguished the best be-
tween the CSF profile groups. A similar trend in re-
sults was found when ROC analyses were stratified by
gender (Table S1, Additional file 1), although AUC
coefficients were overall higher for women (n = 19)
compared to men (n = 33). LASSO logistic regression
with stability selection was performed for the selec-
tion of variables distinguishing between the CSF pro-
file groups with the highest consistency. Nine possible
predictors could be selected, the four novel CSF
markers and the five composite tests presenting each
cognitive domain. Only the test reflecting verbal epi-
sodic memory was selected as a predictor, with selec-
tion frequency (96%) above the cut-off value. All
other possible predictors had a much lower selection
frequency (≤ 20%).
Figure 3 illustrates the ROC curves for the two cogni-
tive domains and the CSF measure with the highest
AUC from Table 3. Verbal episodic memory (AUC =
0.80) was superior in distinguishing between CSF AD vs.
non-AD profiles compared to non-verbal episodic mem-
ory (AUC = 0.65) and CSF GFAP (0.64).
Selection of predictors for scores on each cognitive
domain
LASSO linear regression with a stability selection was ap-
plied for identifying a set of variables (CSF markers and
demographic variables) predicting cognitive scores with
the highest consistency (Fig. 4). Two analyses were per-
formed for each of the five domains, one including all sub-
jects (n = 52) and the other only among those with a CSF
AD profile (n = 28). Variables with stability selection above
75% were considered reliable predictors. GFAP (78%) was
selected as a predictor for executive functions (Fig. 4a)
and age (95%) as a predictor for non-verbal memory
(Fig. 4b) within the whole cohort. Among subjects with a
CSF AD profile, GFAP (87%) and age (81%) were selected
as predictors for processing speed (Fig. 4c) and NFL (80%)
for verbal episodic memory (Fig. 4d). No variables reached
the stability selection criteria as predictors of score reflect-
ing language (Fig. 4e).
Pearson’s correlations between selected CSF markers and
cognitive domains
Relationships between CSF measures and cognitive do-
mains, as selected with LASSO regression—stability
Fig. 2 Pearson’s correlation matrix between CSF markers, age, and length of education. Colored squares indicate statistical significance (p < 0.05).
CSF measures were natural log-transformed
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selection analyses (Fig. 4), were visualized using scatter
plots. It is well established that normal aging and level
and quality of education can influence cognitive test per-
formance [53]. Composite z-scores were therefore ad-
justed for age and education prior to Pearson’s
correlations calculations.
CSF NFL levels did not significantly correlate with ver-
bal episodic memory among all subjects (r = − 0.26, p =
0.06, Fig. 5a). Analysis by CSF profile (Fig. 5b) revealed
moderate, significant correlation among subjects with a
CSF AD profile (r = − 0.43, p = 0.02) compared to none
among those without (r = − 0.05, p = 0.82). Correlations
Table 3 Accuracy in distinguishing between CSF AD and non-AD profiles
Univariable ROC analyses Multivariable LASSO logistic regressionb
AUC 95% CI (AUC)* Stability selection (%)
CSF measuresa
GFAP (ng/ml) 0.64 0.48–0.79 10
YKL-40 (ng/ml) 0.63 0.47–0.78 18
NFL (ng/ml) 0.62 0.45–0.78 2
S100B (pg/ml) 0.61 0.46–0.77 20
Cognitive domains
Verbal episodic memory
Composite z-score 0.80 0.69–0.92 96c
RAVLT delayed recall, score 0.80 0.68–0.93 –
Story delayed recall, score 0.75 0.62–0.89 –
RAVLT immediate recall, score 0.74 0.61–0.88 –
RAVLT recognition-fp, score 0.74 0.61–0.87 –
Story immediate recall, score 0.73 0.59–0.86 –
Non-verbal episodic memory
Composite z-score 0.65 0.50–0.81 14
ROCF immediate recall, score 0.66 0.51–0.81 –
ROCF delayed recall, score 0.65 0.49–0.80 –
Executive functions
Composite z-score 0.64 0.49–0.80 16
TMT-B, secondsa 0.66 0.50–0.81 –
DSST, scorea 0.60 0.44–0.75 –
Stroop 4th/3rd part, secondsa 0.59 0.43–0.75 –
Language
Composite z-score 0.60 0.44–0.76 4
Verbal fluency animals, score 0.68 0.54–0.83 –
Verbal fluency H+S, score 0.50 0.34–0.66 –
Processing speed
Composite z-score 0.56 0.39–0.72 9
TMT-A, secondsa 0.60 0.44–0.76 –
Stroop test—part I, secondsa 0.54 0.38–0.70 –
AUC is the probability that a randomly selected pair of subjects from each CSF profile group is correctly classified
Abbreviations: AD Alzheimer’s disease, AUC area under curve, CI confidence intervals, CSF cerebrospinal fluid, DDST Digit Symbol Substitution Test, fp false
positives, LASSO Least absolute shrinkage and selection operator, RAVLT Rey Auditory-Verbal Learning Test, ROCF Rey–Osterrieth complex figure, TMT Trail
Making Test
*Confidence intervals calculated with DeLong method
aValues are natural log-transformed
bLASSO logistic regression model was fitted on 100 subsamples, with different predictors (CSF measures and composite test scores) possibly selected into each
model. Numbers present the frequency (%) of each possible predictor selected. The per-family error rate (PFER) was set at 1, and the cut-off value at 75% for
stability selection
cThe composite test for verbal episodic memory was the only measure to have selection frequency above the cut-off value
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between the NFL levels and individual neuropsychological
tests reflecting verbal episodic memory are presented in
Additional file 1, S2a-e. T-tau did not reach the selection
criteria for any cognitive domain. It is, nonetheless, of
interest to compare the results of T-tau to NFL as both
proteins are markers of neurodegeneration. The associ-
ation between T-tau and verbal episodic memory was
similar to NFL within the whole cohort (r = − 0.28, p <
0.04, Fig. 5c) but did not reach significance within the CSF
AD group (r = − 0.15, p = 0.45) when analyzed by CSF pro-
file (Fig. 5d).
Correlation between CSF GFAP levels and processing
speed did not reach significance within the whole cohort
(r = − 0.27, p = 0.06, Fig. 5e) or among those with a CSF
non-AD profile (r = 0.02, p = 0.94, Fig. 5f). A moderately
strong correlation was, on the other hand, detected
among those with a CSF AD profile (r = − 0.68, p <
0.001, Fig. 5f). A weak, negative correlation was found
between CSF GFAP levels and executive functions, both
within the whole cohort (r = − 0.37, p = 0.01, Fig. 5g) and
among subjects with a CSF AD profile (r = − 0.39, p =
0.04, Fig. 5h). The corresponding correlations between
CSF GFAP levels with individual neuropsychological
tests reflecting processing speed and executive functions
are presented in Additional file 1, Fig. S3a-e. Additional
file 1 also includes scatter plots identical to those shown
in Fig. 5 without adjustment for age and education (Fig.
S4a-h) and Pearson’s correlations between CSF markers,
age, and education and composite scores of each cogni-
tive domain, both unadjusted and adjusted for age and
education (Table S2).
Discussion
We compared different CSF biomarkers reflecting neu-
rodegeneration (NFL) and inflammation (YKL-40, S100B
and GFAP) in relation to core CSF AD markers and cog-
nitive functions in a cohort of subjects at the pre- and
early symptomatic dementia stages. While our results in-
dicated that these CSF markers did not accurately distin-
guish between AD and non-AD CSF profiles, they
exhibited different patterns of association with certain
cognitive domains, as evaluated by various neuropsycho-
logical tests. This pattern was mainly observed among
subjects with a CSF AD profile. Within that group, levels
of the neurodegeneration marker NFL associated with
verbal episodic memory while inflammatory marker
GFAP associated with processing speed. In addition,
GFAP associated weakly with executive functions within
the whole cohort. Overall, these results indicate that
CSF NFL and GFAP levels do relate to cognitive func-
tions, specifically among those with a CSF AD profile.
Both CSF NFL and YKL-40 levels correlated with T-
tau but not with Aβ42, in accordance with previous stud-
ies [54–56]; thereby, NFL and YKL-40 levels most likely
reflect processes that are independent of Aβ pathology
[55, 57, 58]. The putative inflammatory marker, S100B,
did show a similar trend as YKL-40 within the whole co-
hort, correlating strongly with CSF neurodegeneration
markers (NFL and T-tau) but not with Aβ42 levels. In
contrast, GFAP did not correlate with the CSF neurode-
generation markers nor with CSF Aβ42 levels. Neither
CSF S100B nor GFAP have been much studied in terms
of correlation with CSF core AD markers. Hov et al. [32]
found similar results among elective surgery patients free
from dementia and delirium, with S100B positively cor-
relating with P-tau but not with Aβ42 in CSF. Ishiki et al.
[33] did not find an association between GFAP and the
core AD markers within a sample of healthy subjects
and dementia patients. Here we found that CSF NFL,
YKL-40, S100B, and GFAP all performed poorly in dif-
ferentiating between the CSF AD and non-AD profiles.
In summary, these results are in accordance with previ-
ous findings that have suggested markers NFL, YKL-40,
S100B, and GFAP to be not AD specific.
The neuropsychological tests reflecting verbal episodic
memory did show the best accuracy in differentiating be-
tween the CSF profiles out of all the evaluated cognitive
measures and the novel CSF markers. The accuracy was
good for the composite score of verbal episodic memory
and RAVLT delayed recall test (80%), but fair for all the
other verbal episodic memory tests (between 70 and 80%).
A recent meta-analysis [59] based on 47 studies has shown
that immediate and delayed memory tests consistently
show good accuracy (above 80%) for differentiating be-
tween AD and healthy controls, especially those involving
list recall. Importantly, these studies are based on the
Fig. 3 Comparison between ROC curves of the two cognitive domains
and the CSF marker with the highest area under the curve
(AUC) coefficients
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Fig. 4 LASSO linear regression—stability selection analyses for prediction of composite z-scores reflecting a executive functions, b non-verbal
episodic memory, c processing speed, d verbal episodic memory, and e language. Two analyses were created for each domain, one including all
participants (n = 52) and the other only the CSF AD profile group (n = 28). The cut-off selection value was set at 75% and the per-family error rate
(PFER) at 1 for all analyses
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Fig. 5 (See legend on next page.)
Teitsdottir et al. Alzheimer's Research & Therapy           (2020) 12:92 Page 11 of 14
clinical diagnosis of AD, while our focus was on the signa-
ture of the CSF AD biomarker profile.
CSF markers related in different ways to cognitive
measures. Both CSF NFL [56, 60] and YKL-40 [58] have
been previously reported to associate with cognitive de-
cline, with correlation found between CSF levels and
global cognition assessed by MMSE test scores among
AD patients. In the same studies, the correlation did not
hold for patients with MCI. Thus, NFL and YKL-40
might not be sensitive to very early changes in cognition
in the earliest symptomatic stages of dementia (SCI,
MCI) as in more advanced stages. In this study, the rela-
tionship between NFL and YKL-40 with different cogni-
tive domains within the whole cohort could not be
confirmed. A possible explanation could be that a major-
ity of subjects (n = 34) were at the SCI or MCI stages,
with 23 of those without a CSF AD profile.
Knowledge regarding the relationship between core
CSF biomarkers and cognition remains incomplete.
Overall, Aβ42 and T-tau appear to associate with
memory and executive functions in some studies [61,
62], although results have not been consistent in
terms of which cognitive domains they are associated
with, which particular tests are most suitable and the
strength of relationships in different clinical stages
[61, 63, 64]. However, the levels of core CSF marker
have shown evidence of reaching a plateau early in
the clinical course of the disease and are therefore
not considered ideal for tracking the progression of
disease at later stages [65].
Increased CSF levels of inflammatory marker GFAP
was found weakly associated with worse performance on
tests reflecting executive functions, both within the
whole cohort and among subjects with CSF AD profile.
Few studies have examined the relationship between
CSF GFAP levels and cognitive functions. Ishiki et al.
[33] did not find an association between CSF GFAP
levels and MMSE scores in a sample of healthy subjects
and dementia patients. Darreh-Shori et al. [66] also re-
ported no correlation between CSF GFAP levels and
MMSE scores among AD patients. As with CSF GFAP,
little research has been conducted on the association be-
tween CSF S100B levels and cognition. In the same
study [66], a weak, positive relationship was found be-
tween levels of CSF S100B and MMSE scores within the
same patient group.
Associations between selected CSF markers and cogni-
tive domains were also examined within each CSF pro-
file. CSF NFL levels moderately related to verbal
episodic memory among those with CSF AD profile but
not among those without. Higher levels of CSF GFAP
also moderately associated with worse performance on
processing speed only within the CSF AD profile group.
This is of interest because the CSF markers did not
directly relate to the CSF AD profile (ability in dis-
criminating between CSF profiles was poor). This out-
come could possibly be explained by the additive
effects of distinctive processes on cognitive functions.
A previous study [67] showed a similar trend where
CSF YKL-40 levels associated with less preservation
of global cognition only in individuals with low Aβ
levels (Aβ positive). CSF Aβ levels did though not
correlate with YKL-40 or cognitive decline, but to
brain atrophy in Aβ positive subjects.
This study has several limitations. First, the sample
was relatively small, and hence, present findings need to
be validated in a larger study. The sample did not
include healthy controls, which could underestimate as-
sociations between the studied variables. Another limita-
tion of the study is the lack of information about the
ApoE genotype. However, it is unlikely that the ApoE
genotype affects the outcome as previous studies have
suggested that ApoE ε4 status does not influence CSF
NFL or YKL-40 levels [19, 68, 69].
Conclusions
Our findings suggest that levels of CSF markers NFL
and GFAP relate to different cognitive profiles at the
symptomatic pre- and early dementia stages. The rela-
tionships between the levels of NFL with verbal episodic
memory and GFAP with processing speed were only
observed among those with CSF AD profile, although
the CSF markers did not directly relate to the CSF AD
profile. These CSF markers could be of potential use as
progression markers, monitoring subtle cognitive
changes at the earliest symptomatic stages of dementia
among those with AD pathology. Further studies with
bigger group sizes are needed to validate these results
and to evaluate their potential in tracking changes in the
more advanced stages of AD and other types of
dementia.
(See figure on previous page.)
Fig. 5 Scatter plots presenting Pearson’s correlations between CSF levels of NFL and verbal episodic memory (a, b), T-tau and verbal episodic
memory (c, d), GFAP and processing speed (e, f), and GFAP and executive functions (g, h) within the whole cohort and by CSF profile. *Cognitive
domains were adjusted for covariates (age and education). Without the bottom corner GFAP outlier in the CSF AD profile group, Pearson’s
correlations were slightly lower for f processing speed (r = − 0.58, p = 0.001) and h executive functions (r = − 0.28, p = 0.15)
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Additional file 1: Figure 1. Levels of CSF NFL, YKL-40, S100B and GFAP
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tween CSF profile groups stratified by gender. Figure 2. Pearson’s corre-
lations between levels of CSF NFL with neuropsychological tests
reflecting verbal episodic memory by CSF profile. Figure 3. Pearson’s cor-
relations between levels of CSF GFAP with neuropsychological tests
reflecting processing speed and executive functions by CSF profile. Fig-
ure 4. Pearson’s correlations between CSF levels of NFL and T-tau with
verbal episodic memory and GFAP with processing speed and executive
functions, within the whole cohort and by CSF profile. Table 2. Pearson’s
correlations between CSF markers, age, education and composite z-
scores reflecting cognitive domains.
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